Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 16/20 | 0.66 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.66 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.66 |
| ▸ | PREP | P48147 | 4/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10106774 | 1.00 | DPP4 (0.66) | DPP4DPP8DPP9PREP | |
| SCHEMBL16906202 | 0.89 | DPP4 (0.69) | DPP4DPP8DPP9PREP | |
| SCHEMBL18295428 | 0.89 | DPP4 (0.69) | DPP4DPP8DPP9PREP | |
| SCHEMBL18295466 | 0.83 | PREP (0.55) | DPP4DPP8DPP9PREP | |
| SCHEMBL15129992 | 0.83 | PREP (0.64) | DPP4DPP8DPP9PREP | |
| SCHEMBL15129991 | 0.83 | PREP (0.64) | DPP4DPP8DPP9PREP | |
| SCHEMBL30069138 | 0.82 | MEN1 (0.46) | DPP4DPP8DPP9PREP | |
| SCHEMBL7209480 | 0.82 | DPP4 (0.65) | DPP4DPP8DPP9 | |
| SCHEMBL3815653 | 0.82 | DPP4 (0.65) | DPP4DPP8DPP9 | |
| SCHEMBL23314866 | 0.81 | MEN1 (0.51) | DPP4DPP8DPP9PREP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4483905-A1 | RADIOLABELED FAP-ALPHA-AFFINITY COMPOUND AND USE THEREOF | OSAKA UNIVERSITY (JP) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024026072-A1 | FIBROBLAST ACTIVATION PROTEIN-TARGETED COMPOSITIONS AND METHODS OF USE THEREOF | RATIO THERAPEUTICS, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-117177958-A | Small molecule modulators of alveolar type 2cell proliferation for the treatment of pulmonary diseases | 斯克里普斯研究学院 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023162946-A1 | RADIOLABELED FAPα-AFFINITY COMPOUND AND USE THEREOF | 国立大学法人大阪大学 | 2023-08-31 | — | — | WO | disclosed |
| EP-2804859-B1 | NOVEL FAP INHIBITORS | UNIV ANTWERPEN (BE) | 2019-06-12 | — | — | EP | disclosed |
| US-9346814-B2 | FAP inhibitors | Universiteit Antwerp (BE) | 2016-05-24 | — | — | US | disclosed |
| US-20140357650-A1 | NOVEL FAP INHIBITORS | FOX CHASE CANCER CENTER (US) | 2014-12-04 | — | — | US | disclosed |
| EP-2804859-A1 | NOVEL FAP INHIBITORS | Universiteit Antwerpen (BE) | 2014-11-26 | — | — | EP | disclosed |
| WO-2013107820-A1 | NOVEL FAP INHIBITORS | UNIVERSITEIT ANTWERPEN (BE) | 2013-07-25 | — | — | WO | disclosed |
| US-8178575-B2 | Derivatives of azabicyclo octane, the method of making them and the uses thereof as inhibitors of dipeptidyl peptidase IV | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2012-05-15 | — | — | US | disclosed |
| US-20100016314-A1 | DERIVATIVES OF AZABICYCLO OCTANE, THE METHOD OF MAKING THEM AND THE USES THEREOF AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2010-01-21 | — | — | US | disclosed |
| US-20090176847-A1 | Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2009-07-09 | — | — | US | disclosed |
| EP-2006284-A1 | DICYCLOOCTANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016314-A1 | DERIVATIVES OF AZABICYCLO OCTANE, THE METHOD OF MAKING THEM AND THE USES THEREOF AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV | DPP4, DPP3, DPP8 | DPP4 1/4885DPP8 3/4885DPP9 5/4885 |
| US-20090176847-A1 | Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof | DPP4, DPP7, DPP8 | DPP4 1/4885DPP8 3/4885DPP9 4/4885 |
| US-20140357650-A1 | NOVEL FAP INHIBITORS | FAP, APC, FIBP | DPP4 194/4885DPP8 94/4885DPP9 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.